Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer : current and emerging applications
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) is transforming the management of patients with prostate cancer. In appropriately selected patients, PSMA-PET offers superior sensitivity and specificity compared to conventional imaging (e.g., computed tomography and bone scintigraphy) as well as choline and fluciclovine PET, with the added benefit of consolidating bone and soft tissue evaluation into a single study. Despite being a newly available imaging tool, PSMA-PET has established indications, interpretation guidelines, and reporting criteria, which will be reviewed. The prostate cancer care team, from imaging specialists to those delivering treatment, should have knowledge of physiologic PSMA radiotracer uptake, patterns of disease spread, and the strengths and limitations of PSMA-PET. In this review, current and emerging applications of PSMA-PET, including appropriateness use criteria as well as image interpretation and pitfalls, will be provided with an emphasis on clinical implications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Abdominal radiology (New York) - 49(2024), 4 vom: 19. März, Seite 1288-1305 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moran, Shamus [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Gallium Radioisotopes |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00261-024-04188-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368761665 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368761665 | ||
| 003 | DE-627 | ||
| 005 | 20240323000845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00261-024-04188-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM368761665 | ||
| 035 | |a (NLM)38386156 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moran, Shamus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer |b current and emerging applications |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) is transforming the management of patients with prostate cancer. In appropriately selected patients, PSMA-PET offers superior sensitivity and specificity compared to conventional imaging (e.g., computed tomography and bone scintigraphy) as well as choline and fluciclovine PET, with the added benefit of consolidating bone and soft tissue evaluation into a single study. Despite being a newly available imaging tool, PSMA-PET has established indications, interpretation guidelines, and reporting criteria, which will be reviewed. The prostate cancer care team, from imaging specialists to those delivering treatment, should have knowledge of physiologic PSMA radiotracer uptake, patterns of disease spread, and the strengths and limitations of PSMA-PET. In this review, current and emerging applications of PSMA-PET, including appropriateness use criteria as well as image interpretation and pitfalls, will be provided with an emphasis on clinical implications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Imaging | |
| 650 | 4 | |a PET/CT | |
| 650 | 4 | |a PSMA | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 7 | |a Gallium Radioisotopes |2 NLM | |
| 700 | 1 | |a Cheng, Heather H |e verfasserin |4 aut | |
| 700 | 1 | |a Weg, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Eric H |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Delphine L |e verfasserin |4 aut | |
| 700 | 1 | |a Iravani, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Ippolito, Joseph E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Abdominal radiology (New York) |d 2016 |g 49(2024), 4 vom: 19. März, Seite 1288-1305 |w (DE-627)NLM256750947 |x 2366-0058 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2024 |g number:4 |g day:19 |g month:03 |g pages:1288-1305 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00261-024-04188-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2024 |e 4 |b 19 |c 03 |h 1288-1305 | ||